GLPBio

Apoptosis

Read More about this category

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

 

References:

1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.

2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.

3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.

4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.

5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Research Areas

Products Related to Apoptosis(3379)

  • GC79406 structure
    GC79406SMU-Z1
    CAS: 2410782-66-8
    Purity: >99.00%

    SMU-Z1 is a TLR1/2 heterodimer agonist with an EC 50 of 4.88 nM.

  • GC79417 structure
    GC79417Biotin-itaconate
    CAS: 3086566-93-7
    Purity: >93.00%

    Biotin-itaconate is a biotin-labeled itaconic anhydride that targets PD-L1.

  • GC79421 structure
    GC79421LM-299
    Purity: >95.50%

    LM-299 is a bispecific antibody targeting PD-1 and VEGF with anti-tumor activity.

  • GC79451 structure
    GC79451JP-11646
    CAS: 1902983-63-4
    Purity: >98.50%

    JP-11646 is a pan-PIM inhibitor with increased potency against PIM2 ( IC 50 = 0.5 nM).

  • GC79463 structure
    GC79463NGI-189
    CAS: 2763063-26-7
    Purity: >99.00%

    NGI‑189 is a selective OST‑A inhibitor.

  • GC79465 structure
    GC79465STAT3-IN-52 hydrochloride
    Purity: >96.00%

    STAT3-IN-52 hydrochloride is an orally active STAT3 inhibitor with a K i value of 2.42 μM.

  • GC79473 structure
    GC79473AT-051/43421517
    CAS: 1241957-37-8
    Purity: >99.50%

    AT-051/43421517 is a cytoprotective agent and apoptosis inhibitor that binds to human phosphoglycerate kinase 1 ( hPgk1 ).

  • GC79474 structure
    GC79474(E/Z)-ASK1-IN-4
    CAS: 324566-92-9
    Purity: >98.00%

    (E/Z)-ASK1-IN-4 is an isomer of ASK1-IN-4.

  • GC79475 structure
    GC79475MKK7-JNK activator 1
    CAS: 3100092-62-1
    Purity: >99.50%

    MKK7-JNK activator 1 (Compound 10) is a MKK7-JNK pathway activator.

  • GC79485 structure
    GC79485Siaresinolic acid
    CAS: 511-77-3
    Purity: >98.00%

    Siaresinolic acid is a compound found in the leaves of Sabicea grisea.

  • GC79486 structure
    GC79486Bacoside A (mixture)
    Purity: >98.00%

    Bacoside A (mixture) is a mixture composed of Bacoside A3, Bacopaside II, Bacopaside X and Bacopasaponin C.

  • GC79487 structure
    GC79487(S)-Verapamil
    CAS: 36622-29-4
    Purity: >99.50%

    (S)-Verapamil ((S)-(-)-Verapamil) is an orally active MRP1 (ABCC1) modulator with a K d value of 113 nM for hamster MRP1.

  • GC79496 structure
    GC79496NS-6740
    CAS: 753500-02-6
    Purity: >99.50%

    NS-6740 is a silent agonist of α7 nicotinic acetylcholine receptor ( α7 nAChR ) with an IC 50 of 3 nM.

  • GC79504 structure
    GC79504(R)-Verapamil
    CAS: 38321-02-7
    Purity: >98.50%

    (R)-Verapamil (Dexverapamil) is an optically enantiomer of the oral-active Verapamil.

  • GC79519 structure
    GC79519SKF-96365
    CAS: 162849-90-3
    Purity: >99.50%

    SKF-96365 is a TRPC channel antagonist and store-operated calcium entry ( SOCE ) inhibitor.

  • GC79549 structure
    GC79549FJ9
    CAS: 873841-43-1
    Purity: >98.50%

    FJ9 is a NHERF1/PDZ inhibitor with human NHERF1 PDZ1 IC 50 1540 μM, NHERF1 PDZ2 IC 50 160 μM, and Frizzled-7-Dishevelled PDZ complex K i 10 μM.

  • GC79569 structure
    GC79569Theasinensin C
    CAS: 89013-69-4
    Purity: >98.00%

    Theasinensin C is an orally effective renin inhibitor and gut microbiota modulator, with an IC 50 of 40.21 μM against renin activity.

  • GC79576 structure
    GC795761-(3-Carboxypropyl)-3,7-dimethylxanthine
    CAS: 6493-07-8
    Purity: >98.00%

    1-(3-Carboxypropyl)-3,7-dimethylxanthine is the major circulating oxidative carboxylation metabolite of Pentoxifylline.

  • GC79577 structure
    GC79577PFKFB4-IN-1
    CAS: 2664831-55-2
    Purity: >99.50%

    PFKFB4-IN-1 is a potent and selective ATP-competitive PFKFB4 inhibitor ( IC 50 = 4.50 μM) that reduces intracellular PFKFB4 protein levels.

  • GC79578 structure
    GC79578PrCP-7414
    CAS: 1252037-41-4
    Purity: >99.50%

    PrCP-7414 is a prolyl carboxypeptidase ( PRCP ) inhibitor.

  • GC79675 structure
    GC79675FTO-IN-17
    CAS: 1434867-98-7
    Purity: >98.00%

    FTO-IN-17 is an orally active and brain-penetrant FTO (m 6 A RNA demethylase) inhibitor with an IC 50 of 1.1 μM.

  • GC79709 structure
    GC79709HK2-IN-4
    CAS: 2748366-80-3
    Purity: >99.50%

    HK2-IN-4 is a selective hexokinase 2 ( HK2 ) inhibitor with an IC 50 value of 0.79 μM and a K d value of 0.41 μM.

  • GC79725 structure
    GC79725DI-1548
    CAS: 2247060-97-3
    Purity: >98.00%

    DI-1548 is a potent, selective, and irreversible covalent inhibitor of DCN1 ( IC 50 = 4.6 nM).

  • GC79757 structure
    GC79757ALOX5 stabilizer-1 TFA
    Purity: >98.00%

    ALOX5 stabilizer-1 TFA is an arachidonate 5-lipoxygenase ( ALOX5 ) stabilizer with a K d of 7.26 μM.